Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

View:
Post by MasterAlgae on Jun 09, 2021 9:18am

Marketing...

I think Antibe needs to update its marketing and news-release material under the section:  About Antibe Therapeutics Inc.
The company spent many months and undoubtedly 1000s of dollars to amalgamate so that effort should be reflected in the 'About Us' section of all news releases. It needs to (and should already be) reflect that it owns a strong intellectual property portfolio and has (X number of) patents granted and (X number) of patents pending around the world.
 
For example:
About Antibe Therapeutics Inc.
Antibe is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to address inflammation arising from a wide range of medical conditions. Antibe holds a strong intellectual property portfolio with (x number) of patents granted and (x number) of patents pending around the world. The Company’s current pipeline includes....etc etc

 
Comment by StockingUp21 on Jun 09, 2021 10:38am
almost like they don't know how to run company?
Comment by Hideaway on Jun 09, 2021 11:58am
Their talk re creating shareholder value rings very hollow when CEO disposes of some of his shares at a time when he had left the impression of pending news re several items already well known to posters on this Board.Just like a lot of other biotecs.I sold the majority of my position in IMV a few months ago for similar reasons. Retail investors line their pockets with cash and we get mushroomed ...more  
Comment by 123ABC on Jun 09, 2021 12:16pm
Join the bagholder club friend. Hopefully this gets near my avg so I can sell.
Comment by clubhouse19 on Jun 09, 2021 12:42pm
This is a slow and constant bleed....Imagine if they need money and have to finance below these levels equivalent to 37 cents before consolidation What a mess.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities